oncliveMay 151 min read

FDA Approves T-DXd for Early-Stage HER2+ Breast Cancer

The FDA approved trastuzumab deruxtecan for the adjuvant and neoadjuvant treatment of select early-stage HER2-positive breast cancer.

source

Reporting by onclive. The original article may no longer be reachable at its published URL.

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

oncliveMay 151 min read

The FDA approved trastuzumab deruxtecan for the adjuvant and neoadjuvant treatment of select early-stage HER2-positive breast cancer.

source

Reporting by onclive. The original article may no longer be reachable at its published URL.